Summary.-In patients with disseminated malignant melanoma an optimal method of immunization with irradiated tumour cells was developed by reference to an in vitro assay for circulating specific serum inhibitors of cell mediated cytotoxicity. This immunization protocol consisted of the intradermal inoculation of 2 x 107 irradiated allogeneic melanoma cells admixed with 50 ,ug of percutaneous BCG. This method of immunization induced a significant but transient fall in the specific inhibitory effects of the sera on tumour directed cytotoxic activity of the patients' lymphocytes.
In a pilot group of 30 patients with disseminated malignant melanoma being treated with chemotherapy (DTIC and vincristine) the immunotherapy was given midway between courses of the cytotoxic drugs. There was a correlation between the effects on circulating inhibitor and clinical outcome. The number of objective regressions occurring in this small pilot group was surprisingly high (17/30) and these clinical effects, although obtained in a series without concurrent controls, are presented for discussion.
We suggest that the approach illustrated by this study, employing in vitro assays of tumour directed immune responses, may provide a suitable rational basis for the use of active immunotherapy as an adjunct to chemotherapy in the treatment of malignant disease.
FOR THE RATIONAL application of immunotherapy in human cancer many practical questions have to be answered. What is the best form of treatment? What dose is needed? By what route should it be given? How often? The answers to such questions can be most readily ascertained by examination of the effects of the treatment detected by assays of tumour specific immunological reactions.
Previous studies (Currie, 1973a, b) have suggested that such information may be gleaned by assaying the specific inhibitory effects of the patients' sera on tumour directed cytotoxic lymphocytes. Such studies have incriminated soluble tumour specific antigen in such serum inhibitory effects and, furthermore, they showed that immunization of patients with disseminated malignant melanoma, by inoculation of irradiated melanoma cells, led to a rapid but transient fall in the levels of such antigen in the serum. The use of this assay has allowed the development of immunization procedures in malignant melanoma patients which seem to be optimal for producing such changes, i.e. changing the serum activity from a state of antigen excess to one of antibody excess.
In the course of these earlier studies, which were purely investigative and in no way designed to detect therapeutic effects, occasional unexpected clinical responses occurred. Consequently we were led to perform a pilot study to determine whether active immunotherapy using irradiated tumour cells could be (Luce, 1972 Histological confirmation of the diagnosis was made in all cases but so far examination of the original primary tumours and appropriate grading and classification studies are incomplete.
Immunization procedure.-Melanoma cells obtained as previously described (Currie, Lejeune and Fairley, 1971) , were withdrawn from a liquid nitrogen bank, rapidly thawed at 37°C and washed 3 times in medium 199. They were then counted in a haemacytometer and diluted to give 2 x 107 cells in 0-9 ml of medium 199. After irradiation (10 Krad in a 60Co source) BCG was added.
Percutaneous BCG (Glaxo) was reconstituted and diluted in streptomycin-free medium to a concentration of 500 ug/ml; 0.1 ml of this suspension was then added to the 0 9 ml of tumour cells. This dose of BCG contained approximately 2 x 106 live organisms. This 1 ml of cells and BCG were then inoculated intradermally in 8 distinct sites in one limb at a time. Inoculations were made only into limbs that were macroscopically free of tumour. Each patient in the final protocol received allogeneic cells. For repeated immunizations a different batch of donor cells was emploved each time (i.e. derived from different donor patients). This was done to maximize any possible helper effect due to histocompatibility antigens on the donor cells and to minimize any possible interference by the development of high titre anti-HLA antibodies which might abrogate any such "help ".
Chemotherapy.-5(3,3-dimethyl-triazeno) -imidazole-4-carboxamide (N.S.C. 45388) was administered intravenously at a dose of 2-5 mg/kg body weight for 5 consecutive days. On the first day the patients also received a single intravenous injection of vincristine at a dose of 1@4 mg/M2. Antiemetic drugs were also given to minimize nausea and vomiting. This chemotherapy regimen is remarkably non-toxic. In no patients did sufficient marrow toxicity occur to necessitate changes in the protocol. Very mild peripheral neuropathy, due no doubt to the vincristine, occurred in 2 patients but did not constitute a major problem. In one patient (ME360) the chemotherapy was stopped after 2 courses because she found the nausea distressing. In one further case (ME347) no chemotherapy was given as the patient lived too far away and refused admission to hospital at monthly intervals to receive chemotherapy. The results of this case are included in the Table because this patient showed a dramatic regression, due apparently to immunotherapy alone.
In the week following chemotherapy, occasional patients complained of lassitude, but on the whole the protocol was exceptionally well tolerated.
Combined immunotherapy -chemotherapy protoeol.-In all these studies the patients started treatment with the immunization procedure. There is Ino rationale for this other than the fact that the patients could be investigated without the influence of prior chemotherapy affecting their immunological reactivity.
The major variable in a combined regimen such as this is the time interval between treatments. Currie and Bagshawe (1970) have shown in an animal model that the interval between chemotherapy and any subsequent immunotherapy is of crucial importance. In that particular study an interval of 12-14 days was found to be optimal. In different test systems, however, the intervals needed for an optimal effect may vary. This may well depend on both the tumour studied and the chemotherapeutic agent employed.
The final protocol chosen for the pilot study, based on the animal data of Cu-rie and Bagshawe (1970) Assays of circalcat ing soluble m.elanomiaspecific antigen. Where technically feasible, patients were studied by the in vitro assay previously described which employed shortterm cultures of target cells (Currie and Basham, 1972; Currie, 1973b) . Sera were obtained at frequent intervals before and after treatment and stored at -20°C before testing. They were tested for specific inhibitory activity by incorporation at 5%o into the lymphocyte suspensions before seeding onto melanoma target cells. 
RESULTS

Effects of immrunization with irradiated alloqeneic melanoma cells
Previous studies (Currie, 1973b) have shown that active immunization with irradiated autologous tumour cells leads to a fall in the serum levels of circulating soluble antigen, present either free or bound to antibody. In that the cytotoxicity of peripheral blood lymphocytes from malignant melanoma patients showed a pattern of histogenic cross-reaction (Currie and Basham, 1972) , it was decided to assess the effects of immunization of these patients with irradiated allogeneic melanoma cells. Figure 2 shows the results obtained in 5 patients with disseminated melanoma. In each case there was a dramatic, rapid but transient fall in circulating serum inhibitory activity at least as good as that previously obtained with autologous cells (Currie, 1973b Figure 5 shows the results obtained in 2 women with disease confined to the subcutaneous tissues, although in one (ME352) it was widely disseminated. In both cases the first cycle of treatment led to a profound and sustained fall in inhibitor levels. Objective regression (complete in ME352 and partial in ME360) occurred at the same time. In Case no. ME360, the partial regression (at least 5000 of all measurable disease) was maintained for 11 months, whereas the total regression in ME352 was maintained 9 months before recurrence of a single subcutaneous nodule. Moreover, the patient with maintained partial remission (ME360) lhad received only 2 courses of chemotherapy. In both cases inhibitory activity remained undetectable over the first 6 months.
In Fig. 6 , 2 patients are illustrated who presented with much more advanced disease. Both previously had primary retinal tumours treated surgically and had both presented with subsequent massive liver involvement. Case no. ME345 survived for 13 months after starting treatment and during that time objective regression, as indicated by shrinking of both liver size and of a large palpable epigastric nodule, occurred and lasted approximately 2-3 months. In Case no. ME362 the liver was, at presentation, massively involved and was quite unaffected by the treatment. Subsequent intrahepatic infusion of DTIC gave subjective relief of liver pain but no evidence of objective regression was obtained and she subsequently died 14 weeks after presentation.
There is, as can be seen from Fig. 6 , a striking correlation between the in vitro assay results and the clinical outcome. In ME362 the levelsof circulating inhibitor were high and rose progressively, being virtually unaffected by the treatment, whereas ME345 showed a fall in inhibitory activity after the first 2 immunizations.
The results obtained from the in vitro assays seem to indicate that serial assays of circulating tumour specific inhibitor correlate with the clinical outcome of the combined immunotherapychemotherapy regimen. Furthermore, they support the notion that the immunization procedure is capable of affecting the patient's own tumour directed immunological reactions in a meaningful manner.
Clinical results
The definition of objective regression in malignant melanoma is difficult. By convention such a regression is often defined as a 5000 reduction in the diameter of measurable lesions lasting at least 30 days and in the absence of disease progression elsewhere. Lack of progression of the disease, alone, although possibly an important therapeutic effect is much more difficult to assess. In order to avoid some of the semantic problems associated with such definitions, brief details of the cases treated in this study are shown in the Table, and some of those undergoing objective regression are described in some detail.
ME338. In 1967 this man, then aged 36, noticed an area of pigmented skin on his anterior abdominal wall which was spreading rapidly and eventually started to bleed. This lesion was widely excised and w,as histologically diagnosed as malignant melanoma. At the same time an involved lymph node was removed from his left axilla. After an interval of 6 months another involved lymph node became palpable in the right axilla and this was also excised. One month later a local recurrence was excised from the original primary site. In the following 2 years he developed several subcutaneous metastases on the chest wAall, abdomen and right arm and these were treated with irradiation with some success. Later in 1972, however, his general health deteriorated and he was found to have severe anaemia. This was found to be due to bleeding from the gut and he was managed by periodic blood transfusions. He was referred to this centre complaining of abdominal discomfort and distention. On examination and after detailed investigation, he was found to have a large intra-abdominal mass involving the left para-aortic lymph nodes (by lymphangiography) and a grossly abnormal liver scan. At laparotomy he was found to have a massive retroperitoneal tumour. A superficial lobe of this tumour was invading both duodenum and jejunum and this part of the tumour and involved gut were excised, leaving behind the larger deeper lobe of the tumour. Histologically the mass excised was found to consist of poorly differentiated amelanotic melanoma. He made an excellent recovery from this surgical intervention and subsequently on palpation of the abdomen a fixed mass of approximately 15 cm in diameter could be felt lying to the left of the midline at the level of the umbilicus.
In May 1973 he was immunized with irradiated tumour cells and BCG and started on the combination treatment. During each course of chemotherapy it was noticed in this case that the immunization sites flared up with induration, erythema and tenderness, subsiding again after the cessation of chemotherapy. Over the first 3 months of treatment the palpable abdominal lesion became much smaller in diameter, shrinking to approximately 5 cm in diameter. However, despite this excellent progress he eventually (42 months after starting treatinent) had several grand mal epileptic seizures. Despite negative investigations for cerebral deposits, he was treated with cranial irradiation. Approximately 1 month later he suddenly became extremely ill, developing abdominal obstruction and died. At autopsy the only detectable tumour was the retroperitoneal lesion to which many loops of bowel adhered; his liver, para-aortic lymph nodes and brain were free of disease and the tumour mass consisted of necrotic debris with a small rim of viable tumour.
ME365.-In 1968 this lady, aged 39, noticed that a mole on her left thigh was enlarging and, being a nurse, she asked for it to be removed. Histologically this lesion was reported to be benign. However, 4 years later she developed a pea-size nodule under the excision scar and this was widely excised and found to be a malignant melanoma. Six months later she developed a mass in her left groin and on investigation there was evidence of widespread disease. Apart from the mass of nodes in the left groin, lymphangiography demonstrated massive intrapelvic node involvement on the left side. There were several large lung metastases visible on chest x-ray, and a liver scan showed several cold areas in the right lobe of the liver.
She was therefore started on immunotherapy and chemotherapy. Within 3 months the mass in the left groin had regressed completely and the pelvic mass was much smaller. After a further 3 months, at which time the chemotherapy was stopped, the liver scan was reported as normal, the cold areas having resolved, and the only detectable abnormality at that time was a single small nodule in the lower lobe of her right lung and a small pelvic node on the left side. She continued on monthly immunotherapy and was given a low dose of local irradiation to the lesion in the right lung. Bothi these small residual lesions, in lung and pelvis, have remained static now for 5 months. At 11 months after starting treatment she remains fit and Nell with no evidence of disease elsewhere.
ME352.-This lady, aged 51, presented in 1970 with a primary malignant melanoma on her left calf. This was widely excised and the site skin grafted. She remained well for 2 years until a local subcutaneous recurrence occurred in her left lower leg. At the same time she developed acute appendicitis. At appendicectomy no evidence of intra-abdominal metastasis was found. The local lesion on her leg was excised. However, 6 months later multiple subcutaneous nodules developed on her left leg and these were treated with intra-arterial melphelan. This had no effect and so most of the lesions were surgically excised. Another 6 months later she presented with further deposits on the leg but now there were palpable metastases in the scalp, on the left shoulder and in the left breast. The lesion in her breast and most of those on the leg were excised. Histologically they were all shown to be deposits of malignant melanoma. The subcutaneous lesions on the scalp, on the shoulder and those remaining on the leg were left alone. There was no evidence of visceral involvement from clinical examination or from the investigations performed. She was therefore started on the combiniation treatment protocol.
IMMUNOT11ERAl'Y IN MALIGNANT MELANOMNIA After 3 imontlhs treatmnent, all the nodules regressed completely and she remained wNell for a further 7 months. However, 10 months after starting the treatment local recurrence occurred in the left leg and this was surgically excised. In the 2 wN-eeks following surgery there was a rapid, almost explosive, growth of multiple subcutaneous lesions on the left leg with involvement of lymph nodes in the left groin. She had by this time been off chemnotherapy for 4 months but had continued with monthly immunizations; she was therefore started on DTIC and vincristine again and this produced a transient regression of her recurrent disease which wAas maintained for a further 2 months.
ME382. This patient, a lady aged 44, originally presented in 1960 with a pigmented lesion on her left calf; it had been there for many years but in the previous few wNeeks had grown larger and had occasionally bled. This wNas excised surgically and on histological examination was described as a " junctional naevus with a central nodule showing verv early malignant change". She remained well for a further 12 years after this episode, until discovering a subcutaneous nodule in the left thigh. This was excised and on histological examination shown to be overt malignant melanoma. Six months later the inguinal lymph nodes on the left side became enlarged and she underwent block dissection of the left groin. Two of the excised nodes wNere found to be involved, the uninvolved nodes showing marked reactive hyperplasia. Six months later yet another nodule developed in her left thigh. This was excised and histologically wvas " malignant melanoma consisting of plump spindle cells with abundant mitotic figures ". After yet another 6 months, 2 small nodules of malignant melanoma ere excised from her scalp and this time a chest x-ray revealed the presence of multiple lung metastases.
On examination, she was a healthy looking woman with no evidence of subcutaneous disease or other clinically detectable manifestations of metastatic melanoma. On investigation, the only detectable disease wAas confined to the chest.
She was therefore started on the current immunotherapy-chemotherapy protocol with minor modifications of the chemotherapy. No vincristine wNas given and the dose of DTIC employed -was 250 mg/in2. She tolerated the treatment w-ell, not evein requiring hospitalization for the chemotherapy. After 3 months treatment, the chest x-ray showed evidence of regression of the inetastatic lesions. No further disease has recurred in other sites and she remains extremely fit after a further 6 months.
Of the 30 cases treated in this pilot study, objective regression of disease (partial or complete) occurred in a total of 17 (i.e. 570/o) (Bloom et al., 1973) . Furthermore, nonspecific active treatment with BCG, despite intense investigation, has been shown to be ineffective in maintaining remission in acute lymphoblastic leukaemia (Heyn et al., 1973; MRC, 1971) and in Burkitt's lymphoma (Ziegler and Magrath, 1973) . However, Sokal (1973) In experimental animals such an adjuvant activity of immunotherapy has been described by Haddow and Alexander (1964) . Currie and Bagshawe (1970) have described the successful combination of chemotherapy with a form of immunotherapy and the value of this sort of combination has been confirmed in experimental animals by other workers (Pearsoil et al., 1972) . However, the combination of an immunization procedure with a potentially immunosuppressive form of chemotherapy will obviously be complex. The current enthusiasm for giving chemotherapy intermittently in high doses could perhaps permit the inclusion of an immunization procedure between courses. Cheema and Hersh (1971) have investigated some of the effects of chemotherapy on lymphoid cell function. Many agents given in a single large dose lead to a severe depression of lymphoid cell function which does, however, recover, often with rebound, after 8-10 days. DTIC has little immunosuppressive activity (Bruckner, Mokyr and Mitchell, 1974) and the kinetics of any effect it might have on lymphoid cells is unclear. As DTIC is currently the drug of choice in the treatment of disseminated malignant melanoma, the optimal immunization technique already described was incorporated into a cyclical combination with this drug.
The immunization technique employed in this study was extremely well tolerated. Local reactions at the injection sites were, however, variable. In the majority of patients the local lesions produced rarely caused inconvenience or pain, were usually less than 1 cm in diameter and were not associated with any overt systemic disturbances such as fever, malaise or impaired liver function. After several cycles of treatment, the reactions did become more severe in several patients. After 3 or 4 monthly immunizations the dose of BCG used was halved in those patients whose previous injection site reactions were over 1 cm in diameter. In such hyper-reactive patients, inoculations of allogeneic melanoma cells alone frequently evoked vigorous delayed hypersensitivity reactions. In one case (ME 352) inoculation of autologous tumour cells evoked such a reaction. Unfortunately, autologous cells were not available in most of the cases treated. Where possible, immunization was confined to the upper limbs because inoculation intradermally into the thigh region, especially in women, occasionally led to ulceration, due apparently to local fat necrosis.
It was noticed that in those patients undergoing tumour regression the local immunization site lesions were often more aggressive. In some patients there was little or no reaction around the injection sites; in none of these did tumour regression occur. This finding suggested that the ability of the patients to mount a delayed hypersensitivity reaction may be important in determining the effects of the treatment. An attempt to examine this possibility gave somewhat enigmatic results. Eight of the patients were sensitized to dinitrochlorobenzene 1.54 IMMUNOTHERAPY IN MALIGNANT MELANOMA (DNCB) and then skin tested 14 days later. Three patients were completely unreactive to any test concentration of DNCB whereas the other 5 all gave normal reactions. The 3 negative DNCB cases, however, all produced dramatic local reactions to the BCG-tumour cell innoculum and all 3 underwent objective tumour regression (ME352, ME356, ME-381). One of the DNCB positive cases gave a very brisk delayed hypersensitivity reaction even to the lowest test concentration and yet failed to produce local responses to the BCG and tumour cell mixture or to show any sign of tumour regression. In other words, DNCB skin reactivity did not predict eventual response to the immunization schedule. Whether or not DNCB skin reactivity constitutes a meaningful assay of delayed hypersensitivity reactions in general remains unclear at present.
The number of objective regressions occurring in this small pilot study was surprisingly high. Previous studies at this centre using chemotherapy of various types (including DTIC) have provided a very low incidence of objective regressions. Using DTIC, our experience has not matched that of many other centresof the last 16 cases so treated regression occurred in only one.
Luce and his colleagues (Luce et al., 1970) This study illustrates our approach to the development and clinical applica-155 tion of a form of so-called immunotherapy. We believe that the essential features of such an approach must include assays of the effects of the immunological manipulation employed on some aspect of tumour specific host reactivity. At present an in vitro assay for the detection of circulating soluble tumour specific inhibitory factors seems to be the most appropriate test system for determining the most effective method of immunization and allowing its subsequent incorporation into a combined regimen with chemotherapy.
